

SARCOMA & GIST CONFERENCE 2016

THE MOLECULAR DIVERSITY OF "WILD-TYPE" GIST

Maria Debiec-Rychter, M.D., Ph.D. Department of Human Genetics KU Leuven, Belgium Milan, 15-17 February 2016


esmo.org

DISCLOSURE SLIDE

No conflict of interest to declear




MOLECULAR HETEROGENEITY OF GIST





Boikos&Stratakis, *Endocrine* 2014; 47:401-408 Nannini et al. *BMC Cancer* 2014; 14:685

SDHB-IMMUNOPOSITIVE WT GIST





Miettinen&Lasota, Int J Biochem Cell Biol. 2014 Pantaleo et al. Cancer Med. 2015; 4:101-103


NF-1 ASSOCIATED GIST

- Neurofibromatosis type 1
 - Cuased by germ-line *NF1* mutation (frequency 1/3000)
 - Autosomal dominant inheritance pattern
 - Familial tumor syndrome (benign neurofibromas, MNPST, gliomas, GISTs, juvenilne monocytic leukemia)
- NF-1 GIST
 - 200-fold increased risk of GIST
 - >70% located in the duodenum or small bowel
 - Can be multi-focal
 - ◆ ~90% without activating *KIT/PDGFRA* mutations
 - Activation of the MAPK pathway




Maertens et al. *Hum Mol Genet*. 2006; 15:1015-23 Wang et al. *J Cancer* 2011; 2:90-93


SDHB-IMMUNOPOSITIVE WT GIST



ESVO GOOD SCIENCE BETTER MEDICINI BEST PRACTICE Martens et al. *Human Mol Genet* 2006; 15:1015 Miettinen&Lasota, *Int J Biochem Cell Biol.* 2014 Pantaleo et al. *Cancer Med.* 2015; 4:101-





Pantaleo et al. *Eur J Hum Genet*. 2014; 22:32-39 Boikos&Stratakis, *Endocrine* 2014; 47:401-408 Miettinen&Lasota, *Int J Biochem Cell Biol*. 2014



Killian et al. *Science Transl Med.* 2014; 6:268 Haller et al. *Endocr Relat Cancer* 2014; 21:567-577

SDH-DEFICIENT GIST ARE CHARACTERIZED BY SDH-COMPLEX INACTIVATION





Pantaleo et al. *Eur J Hum Genet*. 2014; 22:32-39 Boikos&Stratakis, *Endocrine* 2014; 47:401-408 Miettinen&Lasota, *Int J Biochem Cell Biol*. 2014

CARNEY-STRATAKIS SYNDROME (CARNEY DYAD)

- Hereditary condition, autosomal dominant inheritance pattern, incomplete penetrace
- Caused by germ-line inactivating mutations of SDHB (10%), SDHC (80%) or SDHD (10%) genes


(the same mutations are found in paraganglioma hereditary syndrome)


- Mutations lead to loss of expression of the protein
- Multifocal, gastric GISTs, SDHB-immunonegative
- Imatinib treatment might be less effective than in sporadic KIT/PDGFRA-mutant GISTs

Pasini et al. *Eur J Hum Genet.* 2008; 16:79-88 Janeway et al. *PNAS* 2011; 108:314-318 Pantaleo et al. *Eur J Hum Genet.* 2014; 22:32-39



DIVERGENCE BETWEEN THE DNA METHYLATION PROFILES OF SDH-DEFICIENT GIST VS. KIT-MUTATED GIST






0.95 0.90 0.85 0.90 0.75 0.70 0.65 0.60 0.55

0.45 0.40 0.35 0.30 0.25 -0.20

0.15

IA & GIST CONFERENCE 2016



Haller et al. Endocr Relat Cancer 2014; 21:567-577

CARNEY TRIAD

Non-familial association of different tumor types

- Multifocal, gastric, epithelioid type of GIST, frequently CD117immunonegative
- **Pulmonary chondromas** (usually multiple)
- Paragangliomas
- Less frequently: Pheochromocytomas / Adrenal adenomas, Esophageal leiomyoma

Female predilection, young age at diagnosis

Lymph node involvement


Caused by primary/de novo SDHC epimutation

- GIST by IHC: SDHB (-), SDHA (+)

Imatinib less effective than for KIT/PDGRA-mutant GIST

ESTOD GOOD SCIENCE BETTER MEDICI BEST PRACTICE Kim et al. Science Transl Med. 2014, 268ra177 Zhang et al. Am J Surg Pathol. 2010; 34:53-64 Matyakhina et al. J Clin Endocrinol Matab. 2007; 92:2938-43

Only 20% all three components



Miettinen&Lasota, Int J Biochem Cell Biol. 2014

NON-SYNDROMIC SDH-DEFICIENT GIST

- Typically occur in children and young adults (85%), female predominance
- Multinodular or multiple, exclusively gastric tumors, common lymphovascular invasion, may remain clinicall stable after metastatic spread
- **50%** have *SDH* gene mutation, often germ-line
 - Most commonly SDHA (30%) SDHA-immunonegative, occur at an older age
 - □ *SDHB*, *SDHC*, *SDHD* (together 20%)
- Hypermethylation of the *SDHC* promoter is an alternative mechanism
- Characterized by the extensive genomic methylation pattern
- Overexpress IGF1R possible target for the therapy



CHARACTERIZATION OF *KIT/PDGFRA-WT GIST*

RAS-P MUTANTS		SDH DEFICIENT		QUADRUPLE WT
NF-1	RAS-BRAF	SDH mutation	No SDH mutation	No RAS-P / No SDH
				mutations
SDHB+	SDHB+	SDHB-	SDHB-	SDHB+
IGF1R-	IGF1R-	IGFR+	IGFR+	IGF1R-
Young adults/	Adults	Pediatric/	Pediatric/	
Adults		Young adults	Young adults	Any age?
		Prevalence of	Prevalence of	
Equal sex	Equal sex	female	female?	Equal sex
Multifocal	Single	Often multifocal	Multifocal?	Single?
	Gastric/			_
Sm.intestine	Sm.intestine	Gastric	Gastric?	Any site?
		Lymph nodes		
		involvement		

KIT/PDGFRA "WILD-TYPE" GIST

- The molecular background and underlying mechanisms of this subtype of GIST are heterogenous
- Once a germline SDHx mutation is found in a patient with SDHdeficient GIST, it is very important to screen other members of the family for the same mutation
- WT GIST are less sensitive to tyrosine kinase inhibition
- Optimization of medical management, including clinical test of novel therapies is needed



KU LEUVEN

maria.debiec-rychter@ med.kuleuven.be



I

